| INTRODUCTION
National Guidelines exist for the investigation and management of drug allergy, including in the perioperative setting. [1] [2] [3] The incidence of perioperative anaesthetic anaphylaxis is uncertain, and access to Specialist allergy services in the UK outside of London and the South East of England has been noted to be patchy and poorly harmonized in the approach to diagnosis and management. 4 There are also NHS National Specialist Service Definitions for allergy B09 and E09. 5, 6 This survey of the provision of specialist perioperative allergy centres was conducted as part of the Royal College of Anaesthetists (RCoA) 6 th National Audit Project (NAP6), studying perioperative anaphylaxis. It aims to describe the provision and practice of specialist allergy services for perioperative anaphylaxis in the UK.
| ME TH ODS
A SurveyMonkey TM questionnaire to ascertain availability, workload and practice in centres providing the specialist assessment of perioperative allergy in the UK was devised (Appendix S1) and distributed to all potential providers of perioperative allergy services in the UK. We arbitrarily defined "larger" adult centres as those seeing ≥20
patients referred for investigation of perioperative hypersensitivity per year and "smaller" centres as those seeing <20, to examine whether there were any differences in the services provided that clearly correlated with workload for standard B1. For MDT related data (mandated in the National Specialist Services
Contracts for Allergy B09 and E09), 5, 6 we defined an MDT as a face-toface or telephonic/video-conferenced multidisciplinary meeting with at least two medical and/or nursing specialties present. We did not count clinics where two or more specialties were present but where the respondents did not report an MDT in the MDT specific question.
| RESULTS
We identified approximately 50 centres providing adult, paediatric or mixed perioperative allergy testing services. The survey was sent to all centres and evaluable responses were received from 47. One respondent submitted no data so was excluded from analysis, and two other services submitted duplicate entries, which were excluded, leaving 44 evaluable responses. Eleven services provided paediatric services alone. Adult services were available in 33 centres, of which five also saw a small number of children.
| Workload
Sixteen adult centres and two paediatric centres reported actual numbers of patients seen and other centres estimated activity for the previous 12 months. (range 1-9). Fifty-three children were investigated for suspected perioperative anaphylaxis over the previous 12 months-46 in specialist paediatric centres and seven in the five combined adult/paediatric centres.
| Access
Considerable geographical variability in distribution of services is shown in Figure 1 ; Regional variation in the number of services and referral patterns related to population size and density in Figure 1B .
| Compliance with standards
Compliance with published standards for each aspect of patient care is presented in (Figure 2A -C).
Overall, the results showed little difference in compliance between larger, smaller or paediatric centres ( Figure 2A -C) for most elements, but notable differences in approach to paediatric cases due to a perception of rarity of NMBA allergy in paediatric cases in some or a wish to avoid or limit distressing testing (like IDT) in most.
As a result, few paediatric centres would strictly meet the BSACI standard of investigating all administered drugs or identifying several or a range of (herein assumed to be at least 2) alternatives.
Standards with greatest variations in practice were the use of NMBA panels and anaesthetists in paediatric clinics, issuing of patient written and verbal information at the clinic visit, provision of information on patient support groups, availability of blood testing for drug specific IgE, routine use of testing to latex or chlorhexidine and direct reporting to MHRA by the clinic.
| Waiting times
Waiting times are shown in Figure 3A -C.
| Adult centres
Urgent appointments were available to most within 5 weeks ( Figure 3A ,B). Most adults were seen within 12 weeks routinely.
Two centres breached current national waiting time targets of 18 weeks-both were larger centres.
There were no major differences in waiting times between larger and smaller centres.
| Paediatric centres
Urgent appointments were available to most within 8 weeks. Routine paediatric appointment waiting times were longer than adults with most waiting >13 weeks ( Figure 3C ).
One centre breached current national targets with a wait of >18 weeks.
3.5 | Staffing 3.5.1 | Leadership
Adult centres
The majority of services (28/33) are led by an allergist or immunologist, with three led by an anaesthetist, one by a respiratory physician and one did not declare a specialty lead.
Of the 21 larger adult centres, 18 were allergist/immunologist-led, and three led by an anaesthetist with drug allergy experience. Of the 12 smaller adult centres, nine are allergist/immunologist-led, one led by an anaesthetist with allergy experience and one by a respiratory physician experienced in allergy and one did not declare a specialty lead.
Paediatric centres
All eleven centres are led by a paediatric allergist.
| Involvement of an anaesthetist

Adult centres
Nine of 21 larger centres and five of 12 smaller centres reported involvement of an allergy-experienced anaesthetist in the clinic. A total of 675 of 1271 (53%) adults were seen in a clinic including an allergyexperienced anaesthetist, of whom 626 (93%) were seen in the nine larger centres. Two further centres (both larger centres) had an anaesthetist without extensive anaphylaxis experience and one reported both.
Paediatric centres
One of eleven paediatric centres reported the involvement of an allergy-experienced anaesthetist.
Overall, eighteen of 44 (41%) centres can be deemed to have appropriate anaesthetist involvement.
| Involvement of a nurse with drug allergy experience
Sixty percent of all centres (26/44) had at least one nurse with drug allergy experience.
Adult centres
Thirteen of 21 larger adult and six of 12 smaller adult centres had an experienced nurse.
Paediatric centres
Seven of eleven paediatric centres had an experienced nurse. While 55% complied with a face-to-face or telephone MDT, if the presence of two specialties in a clinic is judged to be equivalent to an MDT then overall provision rises to 67%.
| Paediatric centres
Five paediatric centres had a face-to-face MDT arrangement (5/11, 45%). Two additional services performed clinics jointly with a paediatric allergist. Only one clinic was staffed by an anaesthetist experienced in drug allergy.
Overall compliance with a face-to-face MDT standard in paediatric clinics was 45% and if the presence of two specialties in a clinic is judged to be equivalent to an MDT then overall compliance rises to 64%.
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| Clinic assessment
Most adult patients (1262/1271, 99%) and all 53 paediatric cases were assessed by face-to-face clinic visits.
Some larger centres offered additional remote diagnostic interpretation and triaging of cases. Two larger adult centres reported additional initial laboratory interpretative investigation of acute reactions for 203 patients, some of whom may have subsequently been triaged to face-to-face clinic visits (information not available).
| Database
Sixty-four percent of all centres reported keeping a database of anaesthetic adverse reaction cases: thirteen larger adult centres (62%), eight smaller adult centres (67%) and seven paediatric centres (64%).
| Referral pathways
All but one clinic reported that they accept consultant-to-consultant referrals to enable rapid and direct assessment.
| Investigations
Considerable variation in practice was revealed both in the repertoire and testing modalities across the survey centres. Centres should be able to investigate all potential culprits in line with the standards above.
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| Pholcodine testing
Six larger adult centres, one smaller centre and one paediatric centre routinely query pholcodine exposure (8/44, 18%). There is no specific standard for testing against pholcodine, but it would be expected to be part of an expert centre's repertoire. 
| Chlorhexidine testing
| Latex
Twenty-three adult centres (14 larger; nine smaller, 70% overall)
reported always testing for latex and nine more in selected cases.
SPT was the preferred first test for 20 (16 larger; four smaller) and sIgE for five (three larger; two smaller) centres. Secondary testing was predominantly sIgE (eight centres) and IDT (three centres). Only larger adult centres used IDT for latex. Compliance is summarized in Figure 2 .
Nine of eleven paediatric centres reported that they always test for latex and two in selected cases. Ten reported using SPT as firstline testing; six reported using sIgE as a second-line test; and none reported using IDT. Five apparently only use a single modality of testing (four SPT, one sIgE) ( Figure 5 ).
| Neuromuscular blocking agents
Panel testing and safe identification of alternative NMBA Practice was highly variable. Compliance is summarized in Figure 2 and Table 1 .
Adult centres Most adult centres (32/33) reported using a "panel" of agents containing many of the routinely available drugs when testing for NMBA allergy (Table 1) Compliance is summarized in Figure 2 and The agents reported to be used routinely in panels are summarized in Table 1 and is broadly comprehensive. Compliance is summarized in Figure 2 .
Paediatric centres
Suxamethonium was routinely used in panels by five paediatric centres but another commented that suxamethonium is rarely used in children and is therefore rarely part of the panel (Table 1 ).
Testing strategies appeared consistent for NMBAs, with most reporting use of SPT first and then IDT if negative; one specified SPT only ( Figure 6 ). Several centres noted the need to minimize distressing IDT testing in children. Few centres used sIgE to thiocholine (suxamethonium and quaternary ammonium groups). One centre reported using sIgE followed by sequential SPT and IDT.
| Drug challenges
No centre performed challenges to NMBAs. Twenty-five of 44 (57%) centres perform challenges to antiemetics; eleven (25%) to hypnotics; 24 (55%) to anxiolytics; 34 (77%) to NSAIDs; 29 (66%) to opioids; and 41 (93%) to local anaesthetics.
Other challenges on offer include heparin, latex, chlorhexidine and paracetamol.
All paediatric centres offered NSAID and local anaesthetic challenges.
Antibiotic challenges
Forty centres (91%) provide antibiotic challenges (20 of 21 larger adults centres; 8 of 12 smaller centres; 11 of 11 paediatric centres).
Waiting times for antibiotic challenges were reported to be under 9 weeks for 21/44 (48%), more than 3 months in 12/43 (28%) of centres and were similar in all types of centre ( Figure 7 ).
| Information
Adherence to relevant guidelines is shown in Figure 2 .
Only half of adult centres give immediate information to the All centres reported that the clinic letter identified the culprit drug when found and all but one identified the nature of the reaction (Figure 2A,B) . Two (5%) centres did not routinely describe the clinical features of the reaction or the clinical tests performed in the clinic letters ( Figure 2B ).
All adult clinic centres reported identifying the drugs or drug groups to avoid and suitable alternatives.
Only six centres reported that they provide details of the alternative diagnosis where IgE-mediated allergy was excluded ( Figure 2B ).
| MHRA reporting
Eleven (25%) centres overall (5 of 21 larger adult, 3 of 12 smaller adult and 3 of 11 paediatric) reported directly to MHRA, the rest relying on the referring clinician to do this ( Figure 2C ).
| DISCUSSION
This is the first UK survey specialist allergy centres evaluating perioperative anaphylaxis and provides important information on the availability and self-reported practice in these services, prior to NAP6 case data collection. Where possible, practice has been mapped to UK recommendations. [1] [2] [3] Most activity occurred in adult centres, but we do not know if this reflects differences in adult or paediatric referral patterns or incidence of anaphylaxis or surgery.
Future analysis of cases reported to NAP6 will provide data on this. Paediatric centres and a few larger adult centres reported the greatest problems with access waiting times and therefore the relationship of staffing and resources appropriate to the workload may need to be explored further. Two-thirds of children had to wait more than 12 weeks to be seen, while more than half of adults waited more than 8 weeks to be seen which may impact on test sensitivity.
Drug sensitization to chlorhexidine is known to be transient 7 so
these delays in assessment run the risk of missing important sensitizations and compromising the diagnostic algorithm.
Access to drug challenge services was also poor, with fewer than half the centres able to challenge to antibiotics within 8 weeks.
Both BSACI and AAGBI guidance mandate a sufficient workload to maintain expertise, and 20 cases were designated by our NAP6 panel to be a reasonable minimum to achieve this. *Any use of an NMBA panel initially or sequentially. Two additional centres said that cis-atracurium would be tested but only where it had been administered at time of the reaction. **Panel including suxamethonium, rocuronium and either atracurium or cis-atracurium as defined by NAP6 (see methods). ***Most paediatric centres choose a limited number of drugs for sequential testing. ****The number of both larger and smaller adult centres using rocuronium may be underestimated by 1 each as one service discontinued prior to the issuing of a clarification query and one larger centre did not respond to repeated clarification queries.
F I G U R E 6 Testing sequence for neuromuscular blocking agents
Smaller clinics and all paediatric clinics might benefit from being part of these governance networks where this is not already the case. The purpose of perioperative drug allergy testing is to identify the culprit drug, plus any cross-reacting drugs to which the patient may also be allergic, thereby to identify safe drugs, particularly when several drugs were co-administered. This should enable the centre to provide a list of drugs to avoid, a list of safe alternatives and a list of drugs that have been excluded as the cause of the allergic reaction.
Not all centres used harmonized protocols for NMBA and routine testing for chlorhexidine and latex, but paediatric centres may have some valid reasons for differences.
We noted marked variability in the adequacy of the NMBA panels Auditing and understanding the best diagnostic algorithm will require harmonized practice in future.
Communication with colleagues appears generally good. Communication with patients may be less good. Most centres reported that they were fully compliant with the recommendations of NICE CG183 regarding specific written information; however, supply of immediate information to patients, written information to patients and information on patient support groups were incomplete on their returns ( Figure 2B ).
Reporting of allergy testing results to the MHRA by clinics is rare and this is usually deferred to the anaesthetist ( Figure 2C ).
While MDT working is not in guidelines it is a national specialist commissioning standard. Only half of the services had a face-to-face MDT to discuss cases. Of concern, anaesthetists were involved in fewer than half of the specialist centres and very rarely in paediatric clinics. Three adult services were led by anaesthetists. Anaesthetists have a key role in detecting non-allergic causes for the clinical presentations, understanding the normal adverse event profile of the drugs given, the confounding effects of polypharmacy and patient comorbidity, advising on suitable future strategies for anaesthesia and ensuring that all likely causes have been considered. 2 More anaesthetists with an interest in allergy are needed to promote learning and enhance service quality. Networking arrangements could be used to ensure anaesthetist involvement in MDT case discussions.
F I G U R E 7 Waiting times for antibiotic challenge
The staffing of clinic services was very variable and may not meet specialist service recommendations and guidance. Specialist nurses with allergy experience were missing in 36%-50% of clinics.
Pharmacist involvement in preparation of drug dilutions for skin tests or challenges was very infrequent but would be desirable.
Diagnostic testing practice must be harmonized. Definitive and translatable predictive values for any testing strategy or sequence remain unknown. SPT remains the initial test of choice for most centres, but follow-up testing and the indications to do so are variable.
Intradermal testing appears to be under-used in comparison with international recommendations overall 1, 8, 9 and this was particularly so in paediatric centres.
Chlorhexidine appeared to be under-investigated and not part of routine testing in many centres, in spite of its ubiquitous (and at times unrecognized) presence in the perioperative environment.
Despite many publications and a suspicion of increasing prevalence of this potentially hidden allergen, many centres did not screen routinely, although all claimed to assess potential exposures. No guideline explicitly states that chlorhexidine testing is mandatory in the investigation of perioperative anaphylaxis, but the variability in testing and the ubiquity of chlorhexidine make this worthy of consideration. In contrast, latex allergy may be becoming less prevalent, yet is still routinely included by most.
From a patient's and clinician's perspective, variability of care is a concern. Our patient representative authors were concerned about low-volume services that rarely see this type of event, or services that do not have harmonized protocols in place for testing of culprit agents and safe alternatives. It was reassuring that no major differences were noted that obviously correlated with service size other than breadth of NMBA panel and fewer MDT discussions. However, this survey did not evaluate differences in the diagnostic accuracy or quality of advice provided by centres, more data on this will be available through NAP6 data analysis. Therefore, the recommendations regarding hub and spoke networking to improve harmonization and quality assurance merit consideration. As recommended in NICE CG183, 3 it was noted that consultant-to-consultant referrals remain an important source of referral.
This survey provides an important snapshot of UK provision and practice in perioperative allergy testing before the main phases of NAP6.
